Julian Sayin’s path to Ohio State happened in a hurry. The five-star quarterback signed with Alabama and enrolled early, but ...

It may look like a laptop we all know, but MSI's latest revision of its slim gaming and power-user Stealth line could be its ...

According to health and wellness group, David Lloyd Clubs, 'bio-syncing' your workout routine is going to be a top trend in ...

Graphene is often described as a wonder material. It is strong, electrically conductive, thermally efficient, and remarkably ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...

BLUETTI will debut the partially bio-based Elite 100 V2 portable power station at CES 2026, featuring a housing made from Covestro’s Bayblend® RE polycarbonate attributed with 25 percent bio-based raw ...

Here's The Post's in-store shopping guide that will save you the embarrassment of buying a gift card (shame on you!) for ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Oak Hill Bio and their partner are developing OHB-607, a recombinant human IGF-1/IGFBP-3 for the prevention of ...

BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 ...

Wave Life Sciences' fair value estimate has been lifted from about $27.21 to roughly $31.60 per share, even as the discount rate holds steady at 6.63% and revenue growth expectations ease from around ...

Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine ...